Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 39 entries
Sorted by: Best Match Show Resources per page
Beyond the computational-representational brain: why affective neuroscience tells us attitudes must be explained on multiple levels.

Frontiers in behavioral neuroscience

Haslacher D.
PMID: 25538584
Front Behav Neurosci. 2014 Dec 04;8:419. doi: 10.3389/fnbeh.2014.00419. eCollection 2014.

No abstract available.

Cite
Haslacher D. Beyond the computational-representational brain: why affective neuroscience tells us attitudes must be explained on multiple levels. Front Behav Neurosci. 2014;8:419doi: 10.3389/fnbeh.2014.00419.
Haslacher, D. (2014). Beyond the computational-representational brain: why affective neuroscience tells us attitudes must be explained on multiple levels. Frontiers in behavioral neuroscience, 8419. https://doi.org/10.3389/fnbeh.2014.00419
Haslacher, David. "Beyond the computational-representational brain: why affective neuroscience tells us attitudes must be explained on multiple levels." Frontiers in behavioral neuroscience vol. 8 (2014): 419. doi: https://doi.org/10.3389/fnbeh.2014.00419
Haslacher D. Beyond the computational-representational brain: why affective neuroscience tells us attitudes must be explained on multiple levels. Front Behav Neurosci. 2014 Dec 04;8:419. doi: 10.3389/fnbeh.2014.00419. eCollection 2014. PMID: 25538584; PMCID: PMC4255623.
Copy Download .nbib Format: NLM
Lattice-gas automata for the Navier-Stokes equation.

Physical review letters

Frisch U, Hasslacher B, Pomeau Y.
PMID: 10032689
Phys Rev Lett. 1986 Apr 07;56(14):1505-1508. doi: 10.1103/PhysRevLett.56.1505.

No abstract available.

Cite
Frisch U, Hasslacher B, Pomeau Y. Lattice-gas automata for the Navier-Stokes equation. Phys Rev Lett. 1986;56(14):1505-1508doi: 10.1103/PhysRevLett.56.1505.
Frisch, U., Hasslacher, B., & Pomeau, Y. (1986). Lattice-gas automata for the Navier-Stokes equation. Physical review letters, 56(14), 1505-1508. https://doi.org/10.1103/PhysRevLett.56.1505
Frisch, et al. "Lattice-gas automata for the Navier-Stokes equation." Physical review letters vol. 56,14 (1986): 1505-1508. doi: https://doi.org/10.1103/PhysRevLett.56.1505
Frisch U, Hasslacher B, Pomeau Y. Lattice-gas automata for the Navier-Stokes equation. Phys Rev Lett. 1986 Apr 07;56(14):1505-1508. doi: 10.1103/PhysRevLett.56.1505. PMID: 10032689.
Copy Download .nbib Format: NLM
Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Schindler C, Birkenfeld AL, Hanefeld M, Schatz U, Köhler C, Grüneberg M, Tschöpe D, Blüher M, Hasslacher C, Bornstein SR.
PMID: 30523582
Diabetes Ther. 2019 Feb;10(1):329-331. doi: 10.1007/s13300-018-0546-6.

In the original publication, the text in Table 2 stated 'Hypersensitivity to the active substance, to Ferinject, or to any of its excipients'.

Cite
Schindler C, Birkenfeld AL, Hanefeld M, et al. Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol. Diabetes Ther. 2019;10(1):329-331doi: 10.1007/s13300-018-0546-6.
Schindler, C., Birkenfeld, A. L., Hanefeld, M., Schatz, U., Köhler, C., Grüneberg, M., Tschöpe, D., Blüher, M., Hasslacher, C., & Bornstein, S. R. (2019). Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol. Diabetes therapy : research, treatment and education of diabetes and related disorders, 10(1), 329-331. https://doi.org/10.1007/s13300-018-0546-6
Schindler, Christoph, et al. "Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 10,1 (2019): 329-331. doi: https://doi.org/10.1007/s13300-018-0546-6
Schindler C, Birkenfeld AL, Hanefeld M, Schatz U, Köhler C, Grüneberg M, Tschöpe D, Blüher M, Hasslacher C, Bornstein SR. Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol. Diabetes Ther. 2019 Feb;10(1):329-331. doi: 10.1007/s13300-018-0546-6. PMID: 30523582; PMCID: PMC6349274.
Copy Download .nbib Format: NLM
Obesity: outcome of standardized life-style change in a rehabilitation clinic. An observational study.

Diabetes, metabolic syndrome and obesity : targets and therapy

Haslacher H, Fallmann H, Waldhäusl C, Hartmann E, Wagner OF, Waldhäusl WK.
PMID: 31213867
Diabetes Metab Syndr Obes. 2019 May 27;12:813-820. doi: 10.2147/DMSO.S197495. eCollection 2019.

No abstract available.

Cite
Haslacher H, Fallmann H, Waldhäusl C, et al. Obesity: outcome of standardized life-style change in a rehabilitation clinic. An observational study. Diabetes Metab Syndr Obes. 2019;12:813-820doi: 10.2147/DMSO.S197495.
Haslacher, H., Fallmann, H., Waldhäusl, C., Hartmann, E., Wagner, O. F., & Waldhäusl, W. K. (2019). Obesity: outcome of standardized life-style change in a rehabilitation clinic. An observational study. Diabetes, metabolic syndrome and obesity : targets and therapy, 12813-820. https://doi.org/10.2147/DMSO.S197495
Haslacher, Helmuth, et al. "Obesity: outcome of standardized life-style change in a rehabilitation clinic. An observational study." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 12 (2019): 813-820. doi: https://doi.org/10.2147/DMSO.S197495
Haslacher H, Fallmann H, Waldhäusl C, Hartmann E, Wagner OF, Waldhäusl WK. Obesity: outcome of standardized life-style change in a rehabilitation clinic. An observational study. Diabetes Metab Syndr Obes. 2019 May 27;12:813-820. doi: 10.2147/DMSO.S197495. eCollection 2019. PMID: 31213867; PMCID: PMC6549422.
Copy Download .nbib Format: NLM
Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis.

Annals of the rheumatic diseases

Simader E, Tobudic S, Mandl P, Haslacher H, Perkmann T, Nothnagl T, Sautner J, Radner H, Winkler F, Burgmann H, Mrak D, Aletaha D, Winkler S, Blüml S.
PMID: 34844927
Ann Rheum Dis. 2021 Nov 29; doi: 10.1136/annrheumdis-2021-221347. Epub 2021 Nov 29.

OBJECTIVES: To assess the kinetics of humoral response after the first and second dose of messenger RNA (mRNA) vaccines in patients with inflammatory joint diseases compared with healthy controls (HC). To analyse factors influencing the quantity of the immune...

Cite
Simader E, Tobudic S, Mandl P, et al. Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-221347.
Simader, E., Tobudic, S., Mandl, P., Haslacher, H., Perkmann, T., Nothnagl, T., Sautner, J., Radner, H., Winkler, F., Burgmann, H., Mrak, D., Aletaha, D., Winkler, S., & Blüml, S. (2021). Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-221347
Simader, Elisabeth, et al. "Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-221347
Simader E, Tobudic S, Mandl P, Haslacher H, Perkmann T, Nothnagl T, Sautner J, Radner H, Winkler F, Burgmann H, Mrak D, Aletaha D, Winkler S, Blüml S. Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. Ann Rheum Dis. 2021 Nov 29; doi: 10.1136/annrheumdis-2021-221347. Epub 2021 Nov 29. PMID: 34844927.
Copy Download .nbib Format: NLM
Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis.

Therapeutic advances in musculoskeletal disease

Studenic P, Alunno A, Sieghart D, Bang H, Aletaha D, Blüml S, Haslacher H, Smolen JS, Gerli R, Steiner G.
PMID: 34539818
Ther Adv Musculoskelet Dis. 2021 Jul 23;13:1759720X211022533. doi: 10.1177/1759720X211022533. eCollection 2021.

AIMS: To determine the diagnostic value of anti-acetylated peptide antibodies (AAPA) in patients with rheumatoid arthritis (RA).METHODS: Three acetylated peptides (ac-lysine, ac-lysine.inv and ac-ornithine) derived from vimentin were employed to measure AAPA by enzyme-linked immunosorbent assay (ELISA) in sera...

Cite
Studenic P, Alunno A, Sieghart D, et al. Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211022533doi: 10.1177/1759720X211022533.
Studenic, P., Alunno, A., Sieghart, D., Bang, H., Aletaha, D., Blüml, S., Haslacher, H., Smolen, J. S., Gerli, R., & Steiner, G. (2021). Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. Therapeutic advances in musculoskeletal disease, 131759720X211022533. https://doi.org/10.1177/1759720X211022533
Studenic, Paul, et al. "Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis." Therapeutic advances in musculoskeletal disease vol. 13 (2021): 1759720X211022533. doi: https://doi.org/10.1177/1759720X211022533
Studenic P, Alunno A, Sieghart D, Bang H, Aletaha D, Blüml S, Haslacher H, Smolen JS, Gerli R, Steiner G. Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2021 Jul 23;13:1759720X211022533. doi: 10.1177/1759720X211022533. eCollection 2021. PMID: 34539818; PMCID: PMC8445531.
Copy Download .nbib Format: NLM
Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival.

Frontiers in immunology

Wahrmann M, Döhler B, Arnold ML, Scherer S, Mayer KA, Haindl S, Haslacher H, Böhmig GA, Süsal C.
PMID: 34497614
Front Immunol. 2021 Aug 23;12:724331. doi: 10.3389/fimmu.2021.724331. eCollection 2021.

The functional Fc gamma receptor (FcγR) IIIA polymorphism

Cite
Wahrmann M, Döhler B, Arnold ML, et al. Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival. Front Immunol. 2021;12:724331doi: 10.3389/fimmu.2021.724331.
Wahrmann, M., Döhler, B., Arnold, M. L., Scherer, S., Mayer, K. A., Haindl, S., Haslacher, H., Böhmig, G. A., & Süsal, C. (2021). Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival. Frontiers in immunology, 12724331. https://doi.org/10.3389/fimmu.2021.724331
Wahrmann, Markus, et al. "Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival." Frontiers in immunology vol. 12 (2021): 724331. doi: https://doi.org/10.3389/fimmu.2021.724331
Wahrmann M, Döhler B, Arnold ML, Scherer S, Mayer KA, Haindl S, Haslacher H, Böhmig GA, Süsal C. Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival. Front Immunol. 2021 Aug 23;12:724331. doi: 10.3389/fimmu.2021.724331. eCollection 2021. PMID: 34497614; PMCID: PMC8420807.
Copy Download .nbib Format: NLM
Basal myokine levels are associated with quality of life and depressed mood in older adults.

Psychophysiology

Mucher P, Batmyagmar D, Perkmann T, Repl M, Radakovics A, Ponocny-Seliger E, Lukas I, Fritzer-Szekeres M, Lehrner J, Knogler T, Tscholakoff D, Fondi M, Wagner OF, Winker R, Haslacher H.
PMID: 33655551
Psychophysiology. 2021 May;58(5):e13799. doi: 10.1111/psyp.13799. Epub 2021 Mar 02.

In an aging society, late-life depression has become an increasing problem. There is evidence that physical activity ameliorates depressive symptoms and increases the quality of life (QoL). However, the underlying mechanisms are still poorly understood. Myokines are molecules secreted...

Cite
Mucher P, Batmyagmar D, Perkmann T, et al. Basal myokine levels are associated with quality of life and depressed mood in older adults. Psychophysiology. 2021;58(5):e13799doi: 10.1111/psyp.13799.
Mucher, P., Batmyagmar, D., Perkmann, T., Repl, M., Radakovics, A., Ponocny-Seliger, E., Lukas, I., Fritzer-Szekeres, M., Lehrner, J., Knogler, T., Tscholakoff, D., Fondi, M., Wagner, O. F., Winker, R., & Haslacher, H. (2021). Basal myokine levels are associated with quality of life and depressed mood in older adults. Psychophysiology, 58(5), e13799. https://doi.org/10.1111/psyp.13799
Mucher, Patrick, et al. "Basal myokine levels are associated with quality of life and depressed mood in older adults." Psychophysiology vol. 58,5 (2021): e13799. doi: https://doi.org/10.1111/psyp.13799
Mucher P, Batmyagmar D, Perkmann T, Repl M, Radakovics A, Ponocny-Seliger E, Lukas I, Fritzer-Szekeres M, Lehrner J, Knogler T, Tscholakoff D, Fondi M, Wagner OF, Winker R, Haslacher H. Basal myokine levels are associated with quality of life and depressed mood in older adults. Psychophysiology. 2021 May;58(5):e13799. doi: 10.1111/psyp.13799. Epub 2021 Mar 02. PMID: 33655551; PMCID: PMC8243943.
Copy Download .nbib Format: NLM
[Myocardial Infarction in an Athlete].

Praxis

Hasslacher S, Wichmann C, Meyer MR, Kurz D, Eberli F.
PMID: 34875866
Praxis (Bern 1994). 2021;110(16):985-990. doi: 10.1024/1661-8157/a003745.

Myocardial Infarction in an Athlete

Cite
Hasslacher S, Wichmann C, Meyer MR, et al. Myokardinfarkt bei einem Sportler. [Myocardial Infarction in an Athlete]. Praxis (Bern 1994). 2021;110(16):985-990doi: 10.1024/1661-8157/a003745.
Hasslacher, S., Wichmann, C., Meyer, M. R., Kurz, D., & Eberli, F. (2021). Myokardinfarkt bei einem Sportler. [Myocardial Infarction in an Athlete]. Praxis, 110(16), 985-990. https://doi.org/10.1024/1661-8157/a003745
Hasslacher, Sebastian, et al. "Myokardinfarkt bei einem Sportler." [Myocardial Infarction in an Athlete]. Praxis vol. 110,16 (2021): 985-990. doi: https://doi.org/10.1024/1661-8157/a003745
Hasslacher S, Wichmann C, Meyer MR, Kurz D, Eberli F. Myokardinfarkt bei einem Sportler. [Myocardial Infarction in an Athlete]. Praxis (Bern 1994). 2021;110(16):985-990. doi: 10.1024/1661-8157/a003745. German. PMID: 34875866.
Copy Download .nbib Format: NLM
Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?.

Therapeutic advances in endocrinology and metabolism

Kulozik F, Hasslacher C.
PMID: 23997930
Ther Adv Endocrinol Metab. 2013 Aug;4(4):113-21. doi: 10.1177/2042018813501188.

OBJECTIVES: In diabetic nephropathy the decline of renal function causes modifications of the insulin and carbohydrate metabolism resulting in changed insulin requirements. The aim of the present study was to identify potential differences in the requirements of human insulin...

Cite
Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?. Ther Adv Endocrinol Metab. 2013;4(4):113-21doi: 10.1177/2042018813501188.
Kulozik, F., & Hasslacher, C. (2013). Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?. Therapeutic advances in endocrinology and metabolism, 4(4), 113-21. https://doi.org/10.1177/2042018813501188
Kulozik, Felix, and Hasslacher, Christoph. "Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?." Therapeutic advances in endocrinology and metabolism vol. 4,4 (2013): 113-21. doi: https://doi.org/10.1177/2042018813501188
Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?. Ther Adv Endocrinol Metab. 2013 Aug;4(4):113-21. doi: 10.1177/2042018813501188. PMID: 23997930; PMCID: PMC3755527.
Copy Download .nbib Format: NLM
Erratum to: Sepsis in standard care: patients' characteristics, effectiveness of antimicrobial therapy and patient outcome-a cohort study.

Infection

Ratzinger F, Eichbichler K, Schuardt M, Tsirkinidou I, Mitteregger D, Haslacher H, Perkmann T, Schmetterer KG, Dorffner G, Burgmann H.
PMID: 26168859
Infection. 2015 Dec;43(6):787. doi: 10.1007/s15010-015-0818-2.

No abstract available.

Cite
Ratzinger F, Eichbichler K, Schuardt M, et al. Erratum to: Sepsis in standard care: patients' characteristics, effectiveness of antimicrobial therapy and patient outcome-a cohort study. Infection. 2015;43(6):787doi: 10.1007/s15010-015-0818-2.
Ratzinger, F., Eichbichler, K., Schuardt, M., Tsirkinidou, I., Mitteregger, D., Haslacher, H., Perkmann, T., Schmetterer, K. G., Dorffner, G., & Burgmann, H. (2015). Erratum to: Sepsis in standard care: patients' characteristics, effectiveness of antimicrobial therapy and patient outcome-a cohort study. Infection, 43(6), 787. https://doi.org/10.1007/s15010-015-0818-2
Ratzinger, Franz, et al. "Erratum to: Sepsis in standard care: patients' characteristics, effectiveness of antimicrobial therapy and patient outcome-a cohort study." Infection vol. 43,6 (2015): 787. doi: https://doi.org/10.1007/s15010-015-0818-2
Ratzinger F, Eichbichler K, Schuardt M, Tsirkinidou I, Mitteregger D, Haslacher H, Perkmann T, Schmetterer KG, Dorffner G, Burgmann H. Erratum to: Sepsis in standard care: patients' characteristics, effectiveness of antimicrobial therapy and patient outcome-a cohort study. Infection. 2015 Dec;43(6):787. doi: 10.1007/s15010-015-0818-2. PMID: 26168859.
Copy Download .nbib Format: NLM
Copeptin: Prognostic Relevance as a Perioperative Marker in Pediatric Cardiac Surgery.

The Annals of thoracic surgery

Urganci E, Marculescu R, Michel-Behnke I, Hornykewycz S, Base E, Golej J, Faybik P, Haslacher H, Laufer G, Zimpfer D, Herbst C.
PMID: 33285135
Ann Thorac Surg. 2020 Dec 04; doi: 10.1016/j.athoracsur.2020.11.017. Epub 2020 Dec 04.

BACKGROUND: Copeptin is a cleavage product of vasopressin. This study aimed to figure out if copeptin would be a suitable biomarker in patients with congenital heart disease in the postoperative course.METHODS: The primary outcome endpoint of this study was...

Cite
Urganci E, Marculescu R, Michel-Behnke I, et al. Copeptin: Prognostic Relevance as a Perioperative Marker in Pediatric Cardiac Surgery. Ann Thorac Surg. 2020;doi: 10.1016/j.athoracsur.2020.11.017.
Urganci, E., Marculescu, R., Michel-Behnke, I., Hornykewycz, S., Base, E., Golej, J., Faybik, P., Haslacher, H., Laufer, G., Zimpfer, D., & Herbst, C. (2020). Copeptin: Prognostic Relevance as a Perioperative Marker in Pediatric Cardiac Surgery. The Annals of thoracic surgery, . https://doi.org/10.1016/j.athoracsur.2020.11.017
Urganci, Erhan, et al. "Copeptin: Prognostic Relevance as a Perioperative Marker in Pediatric Cardiac Surgery." The Annals of thoracic surgery vol. (2020). doi: https://doi.org/10.1016/j.athoracsur.2020.11.017
Urganci E, Marculescu R, Michel-Behnke I, Hornykewycz S, Base E, Golej J, Faybik P, Haslacher H, Laufer G, Zimpfer D, Herbst C. Copeptin: Prognostic Relevance as a Perioperative Marker in Pediatric Cardiac Surgery. Ann Thorac Surg. 2020 Dec 04; doi: 10.1016/j.athoracsur.2020.11.017. Epub 2020 Dec 04. PMID: 33285135.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 39 entries